Inglyflo 10 mg & 25 mg FC tablets

    Inglyflo 10 mg & 25 mg FC tablets

    S4
    PDF Leaflet Revision Date: 17 February 2026


    Clinical Summary

    Quick overview from the medicine insert

    Indication

    Adjunct to diet and exercise for type 2 diabetes mellitus.

    Dosage (summary)

    Starting dose: 10 mg once daily; may increase to 25 mg once daily.

    Special Populations

    • Renal impairment
    • Hepatic impairment
    • Elderly patients

    Pregnancy & Breastfeeding

    Contraindicated in pregnancy and breastfeeding.

    Key Drug Interactions

    • Diuretics
    • Lithium

    Contraindications

    • Type 1 diabetes
    • Ketoacidosis
    • Moderate to severe renal impairment
    • Pregnancy
    • Lactation

    Common side effects

    • Hypoglycaemia
    • Increased urination
    • Genital infections

    Counselling Points

    • Monitor for signs of ketoacidosis
    • Stay hydrated
    • Report genital infections

    Serious warnings

    • Risk of diabetic ketoacidosis
    • Volume depletion
    • Necrotising fasciitis
    Important Disclaimer

    The Inglyflo 10 mg & 25 mg FC tablets professional information leaflet below is the property of Dr Reddy’S Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

    Healthcare Professionals Only

    This content is for registered healthcare professionals

    Sign in or create a free account to read the full package insert.

    Free for HPCSA-registered professionals. Powered by Medinsert.

    Successfully Stashed! 💊

    This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

    View My Favourites
    WhatsApp Email LinkedIn